Acitretin mitigates uroporphyrin-induced bone defects in congenital erythropoietic porphyria models
J. Bragazzi Cunha, J. S. Elenbaas, D. Maitra, N. Kuo, R. Azuero-Dajud, A. C. Ferguson, M. S. Griffin, S. I. Lentz, J. A. Shavit, B. Omary
This study identifies acitretin as a potential treatment for congenital erythropoietic porphyria by mitigating uroporphyrin-induced bone defects in a zebrafish model.
bioRxiv · Mar 30, 2021Pathology